Rucaparib, also known as AG-14699 or PF-01367338, is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Rucaparib selectively binds to PARP1 and inhibits PARP1-mediated DNA repair, thereby enhancing the accumulation of DNA strand breaks and promoting genomic instability and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy.
Related Prodcuts:
GW9662; TAS-103; TAS-103 dihydrochloride; BRD73954; PU-WS13; L189; SCR7; Ispinesib; Dasabuvir; Ellipticine; Rucaparib; Rucaparib camsylate; CB-5083; Maytansinoid DM 1; Mirin; Dasabuvir sodium; Dexrazoxane Hydrochloride; Nedaplatin; CAY10572